Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 12%
Buy 35%
Hold 53%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. demonstrated a significant increase in its employee count, totaling 1,333 at year-end 2025, reflecting a commitment to growth and expanding operational capacity. The company also experienced a notable rise in advertising expenses, which reached $114.9 million in 2025, indicating a strategic investment in marketing to drive sales and brand awareness. Furthermore, projections for the global high-frequency neurostimulation (HGNS) market suggest sustained double-digit sales growth, with Inspire poised to benefit from an estimated 11% and 16% year-over-year growth in 2027 and 2028, respectively, promising a robust financial outlook.

Bears say

Inspire Medical Systems Inc has lowered its revenue guidance for FY 2026 from an anticipated range of $1,003-$1,013 million to $950-$1,000 million, reflecting concerns about reimbursement uncertainties and a decelerating domestic growth trajectory. The company faces additional headwinds due to confusion surrounding new coding for its reimbursement and potential disincentives for ENT surgeons to perform procedures involving its Inspire system. Given these challenges, coupled with a rocky initial rollout of the WISeR program and potential impacts on case approvals, a lower valuation multiple seems warranted as investors may perceive these issues as persistent overhangs on future growth.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 12% of analysts recommend a Strong Buy, 35% recommend Buy, 53% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.